Metabolic–Bariatric Surgery in Patients with Insulin Resistance and Uncontrolled Arterial Hypertension: Current Selection Criteria and Mid-Term Metabolic and Cardiovascular Outcomes
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Insulin resistance and uncontrolled arterial hypertension represent central components of cardiometabolic disease and are strongly linked to obesity through complex metabolic, inflammatory, neurohormonal, and vascular mechanisms. Dysfunctional adipose tissue, chronic inflammation, and ectopic fat deposition contribute to impaired insulin signaling, endothelial dysfunction, and increased arterial stiffness, thereby promoting both type 2 diabetes mellitus and hypertension. Within this pathophysiological context, metabolic–bariatric surgery has emerged as an effective therapeutic strategy that extends beyond weight reduction, directly targeting the mechanisms underlying cardiometabolic risk. Traditional eligibility criteria for metabolic–bariatric surgery have relied primarily on body mass index thresholds; however, growing evidence highlights the limitations of this approach in metabolically unhealthy individuals. Contemporary selection strategies increasingly incorporate metabolic markers such as insulin resistance indices, uncontrolled hypertension despite pharmacological therapy, and comprehensive cardiovascular risk stratification, including evidence of target-organ damage. Surgical techniques such as sleeve gastrectomy and Roux-en-Y gastric bypass induce profound hormonal and metabolic adaptations, including enhanced incretin secretion, altered bile acid signaling, and reductions in ectopic fat, leading to early and sustained improvements in insulin sensitivity and glucose homeostasis. Emerging procedures, including one-anastomosis gastric bypass variants, offer additional options for patients with refractory metabolic disease. Mid-term outcomes consistently demonstrate durable improvements in glycemic control, significant rates of diabetes and hypertension remission, favorable changes in lipid profiles, and reductions in systemic inflammation. These metabolic benefits translate into meaningful cardiovascular improvements, including reduced arterial stiffness, regression of left ventricular hypertrophy, and a substantial decrease in major adverse cardiovascular events and mortality. The magnitude of benefit is influenced by baseline metabolic severity, surgical technique, postoperative weight loss, and adherence to long-term lifestyle modification and follow-up. Collectively, current evidence supports metabolic–bariatric surgery as a cornerstone intervention in selected patients with insulin resistance and uncontrolled hypertension, integrating surgical therapy into comprehensive cardiometabolic risk management.
Fields of Study & Subjects
Bariatric Surgery and Outcomes
Diabetes
Cardiovascular Risks
and Lipoproteins
Minimally Invasive Surgical Techniques
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 28 March 2026
- Language
- EN